Recent developments in preclinical DNA vaccination

Vaccines

Volumn 2, Issue 1, 2014, Pages 89-106

  Okuda, Kenji ^a,b,c   Wada, Yoshiyuki ^c   Shimada, Masaru ^a  

^a YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b Choju Medical Institute   (Japan)

^c Vaccine Institute   (Japan)

Author keywords

DNA vaccine; Electroporation; Genetic adjuvants

Indexed keywords

DNA VACCINE; HUMAN GROWTH HORMONE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN A; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 12; PLASMID DNA; RNA VACCINE; VIRUS ANTIGEN;

CD8+ T LYMPHOCYTE; CLINICAL TRIAL (TOPIC); CYTOTOXICITY; DNA IMMUNIZATION; ELECTROPORATION; ENHANCER REGION; ENZYME LINKED IMMUNOSPOT ASSAY; GENE DELIVERY SYSTEM; GENE GUN IMMUNIZATION; GENE INSERTION; GENE TARGETING; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA VIRUS; MOLECULAR CLONING; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; REVIEW;

EID: 84906794766     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines2010089     Document Type: Review

References (79)

1. Alarcon, J.B.; Waine, G.W.; McManus, D.P. DNA vaccines: Technology and application as anti-parasite and anti-microbial agents. Adv. Parasitol. 1999, 42, 343-410.
2. Bins, A.D.; van den Berg, J.H.; Oosterhuis, K.; Haanen, J.B. Recent advances towards the clinical application of DNA vaccines. Neth. J. Med. 2013, 71, 109-117.
3. Robinson, H.L.; Pertmer, T.M. DNA vaccines for viral infections: Basic studies and applications. Adv. Virus Res. 2000, 55, 1-74.
4. Ledgerwood, J.E.; Graham, B.S. DNA vaccines: A safe and efficient platform technology for responding to emerging infectious diseases. Hum. Vaccin. 2009, 5, 623-626.
5. Martin, J.E.; Sullivan, N.J.; Enama, M.E.; Gordon, I.J.; Roederer, M.; Koup, R.A.; Bailer, R.T.; Chakrabarti, B.K.; Bailey, M.A.; Gomez, P. L.; et al. A DNA vaccine for Ebola virus is safe and immunogenic in a Phase I clinical trial. Clin. Vaccine Immunol. 2006, 13, 1267-1277.
6. Martin, J.E.; Pierson, T.C.; Hubka, S.; Rucker, S.; Gordon, I.J.; Enama, M.E.; Andrews, C.A.; Xu, Q.; Davis, B.S.; Nason, M.; et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a Phase 1 clinical trial. J. Infect. Dis. 2007, 196, 1732-1740.
7. Martin, J.E.; Louder, M.K.; Holman, L.A.; Gordon, I.J.; Enama, M.E.; Larkin, B.D.; Andrews, C.A.; Vogel, L.; Koup, R.A.; Roederer, M.; et al. A SARS DNA vaccine induces neutralizing antibody and cellular immune responses in healthy adults in a Phase I clinical trial. Vaccine 2008, 26, 6338-6343.
8. Ledgerwood, J.E.; Pierson, T.C.; Hubka, S.A.; Desai, N.; Rucker, S.; Gordon, I.J.; Enama, M.E.; Nelson, S.; Nason, M.; Gu, W.; et al. A West Nile virus DNA vaccine utilizing a modified promoter induces neutralizing antibody in younger and older healthy adults in a phase I clinical trial. J. Infect. Dis. 2011, 203, 1396-1404.
9. Ledgerwood, J.E.; Wei, C.J.; Hu, Z.; Gordon, I.J.; Enama, M.E.; Hendel, C.S.; McTamney, P.M.; Pearce, M.B.; Yassine, H.M.; Boyington, J. C.; et al. DNA priming and influenza vaccine immunogenicity: Two Phase 1 open label randomised clinical trials. Lancet Infect. Dis. 2011, 11, 916-924.
10. Tang, D.C.; DeVit, M.; Johnston, S.A. Genetic immunization is a simple method for eliciting an immune response. Nature 1992, 356, 152-154.
11. Chang, D.C.; Liu, W.J.; Anraku, I.; Clark, D.C.; Pollitt, C.C.; Suhrbier, A.; Hall, R.A.; Khromykh, A.A. Single-round infectious particles enhance immunogenicity of a DNA vaccine against West Nile virus. Nat. Biotechnol. 2008, 26, 571-577.
12. Coban, C.; Kobiyama, K.; Aoshi, T.; Takeshita, F.; Horii, T.; Akira, S.; Ishii, K.J. Novel strategies to improve DNA vaccine immunogenicity. Curr. Gene Ther. 2011, 11, 479-484.
13. Sommerset, I.; Krossoy, B.; Biering, E.; Frost, P. Vaccines for fish in aquaculture. Expert Rev. Vaccines 2005, 4, 89-101.
14. Bar-Or, A.; Vollmer, T.; Antel, J.; Arnold, D.L.; Bodner, C.A.; Campagnolo, D.; Gianettoni, J.; Jalili, F.; Kachuck, N.; Lapierre, Y.; et al. Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial. Arch. Neurol. 2007, 64, 1407-1415.
15. Papadopoulou, A.; von Felten, S.; Traud, S.; Rahman, A.; Quan, J.; King, R.; Garren, H.; Steinman, L.; Cutter, G.; Kappos, L.; et al. Evolution of MS lesions to black holes under DNA vaccine treatment. J. Neurol. 2012, 259, 1375-1382.
16. Lambracht-Washington, D.; Rosenberg, R.N. Active DNA Aβ42 vaccination as immunotherapy for Alzheimer disease. Transl. Neurosci. 2012, 3, 307-313.
17. Jounai, N.; Okuda, K.; Kojima, Y.; Toda, Y.; Hamajima, K.; Ohba, K.; Klinman, D.; Xin, K.Q. Contribution of the rev gene to the immunogenicity of DNA vaccines targeting the envelope glycoprotein of HIV. J. Gene Med. 2003, 5, 609-617.
18. Shoji, M.; Yoshizaki, S.; Mizuguchi, H.; Okuda, K.; Shimada, M. Immunogenic comparison of chimeric adenovirus 5/35 vector carrying optimized human immunodeficiency virus clade C genes and various promoters. PLoS One 2012, 7, e30302.
19. Ulmer, J.B.; Deck, R.R.; DeWitt, C.M.; Friedman, A.; Donnelly, J.J.; Liu, M.A. Protective immunity by intramuscular injection of low doses of influenza virus DNA vaccines. Vaccine 1994, 12, 1541-1544.
20. Barry, M.A.; Lai, W.C.; Johnston, S.A. Protection against mycoplasma infection using expression-library immunization. Nature 1995, 377, 632-635.
21. Donnelly, J.J.; Friedman, A.; Martinez, D.; Montgomery, D.L.; Shiver, J.W.; Motzel, S.L.; Ulmer, J.B.; Liu, M.A. Preclinical efficacy of a prototype DNA vaccine: Enhanced protection against antigenic drift in influenza virus. Nat. Med. 1995, 1, 583-587.
22. Widera, G.; Austin, M.; Rabussay, D.; Goldbeck, C.; Barnett, S.W.; Chen, M.; Leung, L.; Otten, G.R.; Thudium, K.; Selby, M. J.; et al. Increased DNA vaccine delivery and immunogenicity by electroporation in vivo. J. Immunol. 2000, 164, 4635-4640.
23. DeMuth, P.C.; Min, Y.; Huang, B.; Kramer, J.A.; Miller, A.D.; Barouch, D.H.; Hammond, P.T.; Irvine, D.J. Polymer multilayer tattooing for enhanced DNA vaccination. Nat. Mater. 2013, 12, 367-376.
24. Feltquate, D.M.; Heaney, S.; Webster, R.G.; Robinson, H.L. Different T helper cell types and antibody isotypes generated by saline and gene gun DNA immunization. J. Immunol. 1997, 158, 2278-2284.
25. Boyle, C.M.; Morin, M.; Webster, R.G.; Robinson, H. L. Role of different lymphoid tissues in the initiation and maintenance of DNA-raised antibody responses to the influenza virus H1 glycoprotein. J. Virol. 1996, 70, 9074-9078.
26. Fynan, E.F.; Webster, R.G.; Fuller, D.H.; Haynes, J.R.; Santoro, J.C.; Robinson, H.L. DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations. Proc. Natl. Acad. Sci. USA 1993, 90, 11478-11482.
27. Tadokoro, K.; Koizumi, Y.; Miyagi, Y.; Kojima, Y.; Kawamoto, S.; Hamajima, K.; Okuda, K.; Tanaka, S.; Onari, K.; Wahren, B.; et al. Rapid and wide-reaching delivery of HIV-1 env DNA vaccine by intranasal administration. Viral Immunol. 2001, 14, 159-167.
28. Okada, E.; Sasaki, S.; Ishii, N.; Aoki, I.; Yasuda, T.; Nishioka, K.; Fukushima, J.; Miyazaki, J.; Wahren, B.; Okuda, K. Intranasal immunization of a DNA vaccine with IL-12- and granulocyte-macrophage colony-stimulating factor (GM-CSF)-expressing plasmids in liposomes induces strong mucosal and cell-mediated immune responses against HIV-1 antigens. J. Immunol. 1997, 159, 3638-3647.
29. Asakura, Y.; Hinkula, J.; Leandersson, A.C.; Fukushima, J.; Okuda, K.; Wahren, B. Induction of HIV-1 specific mucosal immune responses by DNA vaccination. Scand. J. Immunol. 1997, 46, 326-330.
30. Wang, D.; Christopher, M.E.; Nagata, L.P.; Zabielski, M.A.; Li, H.; Wong, J.P.; Samuel, J. Intranasal immunization with liposome-encapsulated plasmid DNA encoding influenza virus hemagglutinin elicits mucosal, cellular and humoral immune responses. J. Clin. Virol. 2004, 31, S99-S106.
31. Liu, L.J.; Watabe, S.; Yang, J.; Hamajima, K.; Ishii, N.; Hagiwara, E.; Onari, K.; Xin, K.Q.; Okuda, K. Topical application of HIV DNA vaccine with cytokine-expression plasmids induces strong antigen-specific immune responses. Vaccine 2001, 20, 42-48.
32. Watabe, S.; Xin, K.Q.; Ihata, A.; Liu, L.J.; Honsho, A.; Aoki, I.; Hamajima, K.; Wahren, B.; Okuda, K. Protection against influenza virus challenge by topical application of influenza DNA vaccine. Vaccine 2001, 19, 4434-4444.
33. Daheshia, M.; Kuklin, N.; Kanangat, S.; Manickan, E.; Rouse, B.T. Suppression of ongoing ocular inflammatory disease by topical administration of plasmid DNA encoding IL-10. J. Immunol. 1997, 159, 1945-1952.
34. Kask, A.S.; Chen, X.; Marshak, J.O.; Dong, L.; Saracino, M.; Chen, D.; Jarrahian, C.; Kendall, M.A.; Koelle, D.M. DNA vaccine delivery by densely-packed and short microprojection arrays to skin protects against vaginal HSV-2 challenge. Vaccine 2010, 28, 7483-7491.
35. Okuda, K.; Xin, K.Q.; Haruki, A.; Kawamoto, S.; Kojima, Y.; Hirahara, F.; Okada, H.; Klinman, D.; Hamajima, K. Transplacental genetic immunization after intravenous delivery of plasmid DNA to pregnant mice. J. Immunol. 2001, 167, 5478-5484.
36. +T-cell responses after rAd5 boost in a randomized clinical trial. PLoS One 2013, 8, e59340.
37. Tavel, J.A.; Martin, J.E.; Kelly, G.G.; Enama, M.E.; Shen, J.M.; Gomez, P.L.; Andrews, C.A.; Koup, R.A.; Bailer, R.T.; Stein, J. A.; et al. Safety and immunogenicity of a Gag-Pol candidate HIV-1 DNA vaccine administered by a needle-free device in HIV-1-seronegative subjects. J. Acquir. Immune Defic. Syndr. 2007, 44, 601-605.
38. Sardesai, N.Y.; Weiner, D.B. Electroporation delivery of DNA vaccines: Prospects for success. Curr. Opin. Immunol. 2011, 23, 421-429.
39. Luxembourg, A.; Hannaman, D.; Ellefsen, B.; Nakamura, G.; Bernard, R. Enhancement of immune responses to an HBV DNA vaccine by electroporation. Vaccine 2006, 24, 4490-4493.
40. Vasan, S.; Hurley, A.; Schlesinger, S.J.; Hannaman, D.; Gardiner, D.F.; Dugin, D.P.; Boente-Carrera, M.; Vittorino, R.; Caskey, M.; Andersen, J.; et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011, 6, e19252.
41. Luckay, A.; Sidhu, M.K.; Kjeken, R.; Megati, S.; Chong, S.Y.; Roopchand, V.; Garcia-Hand, D.; Abdullah, R.; Braun, R.; Montefiori, D. C.; et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in Rhesus macaques. J. Virol. 2007, 81, 5257-5269.
42. +T cells in mice. J. Clin. Invest. 2013, 123, 2629-2642.
43. Donate, A.; Coppola, D.; Cruz, Y.; Heller, R. Evaluation of a novel non-penetrating electrode for use in DNA vaccination. PLoS One 2011, 6, e19181.
44. Brave, A.; Nystrom, S.; Roos, A.K.; Applequist, S.E. Plasmid DNA vaccination using skin electroporation promotes poly-functional CD4 T-cell responses. Immunol. Cell Biol. 2011, 89, 492-496.
45. Heller, L.C.; Heller, R. Electroporation gene therapy preclinical and clinical trials for melanoma. Curr. Gene Ther. 2010, 10, 312-317.
46. Bordbar, B.; Gnidehou, S.; Ndam, N.T.; Doritchamou, J.; Moussiliou, A.; Quiviger, M.; Deloron, P.; Scherman, D.; Bigey, P. Electroporation-mediated genetic vaccination for antigen mapping: application to Plasmodium falciparum VAR2CSA protein. Bioelectrochemistry 2012, 87, 132-137.
47. Romero, E.L.; Morilla, M.J. Topical and mucosal liposomes for vaccine delivery. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol. 2011, 3, 356-375.
48. Ishii, N.; Fukushima, J.; Kaneko, T.; Okada, E.; Tani, K.; Tanaka, S.I.; Hamajima, K.; Xin, K.Q.; Kawamoto, S.; Koff, W.; et al. Cationic liposomes are a strong adjuvant for a DNA vaccine of human immunodeficiency virus type 1. AIDS Res. Hum. Retroviruses 1997, 13, 1421-1428.
49. Xin, K.Q.; Hamajima, K.; Sasaki, S.; Honsho, A.; Tsuji, T.; Ishii, N.; Cao, X.R.; Lu, Y.; Fukushima, J.; Shapshak, P.; et al. Intranasal administration of human immunodeficiency virus type-1 (HIV-1) DNA vaccine with interleukin-2 expression plasmid enhances cell-mediated immunity against HIV-1. Immunology 1998, 94, 438-444.
50. Tsuji, T.; Hamajima, K.; Fukushima, J.; Xin, K.Q.; Ishii, N.; Aoki, I.; Ishigatsubo, Y.; Tani, K.; Kawamoto, S.; Nitta, Y.; et al. Enhancement of cell-mediated immunity against HIV-1 induced by coinnoculation of plasmid-encoded HIV-1 antigen with plasmid expressing IL-12. J. Immunol. 1997, 158, 4008-4013.
51. Yi, A.K.; Chace, J.H.; Cowdery, J.S.; Krieg, A.M. IFN-gamma promotes IL-6 and IgM secretion in response to CpG motifs in bacterial DNA and oligodeoxynucleotides. J. Immunol. 1996, 156, 558-564.
52. Sasaki, S.; Sumino, K.; Hamajima, K.; Fukushima, J.; Ishii, N.; Kawamoto, S.; Mohri, H.; Kensil, C.R.; Okuda, K. Induction of systemic and mucosal immune responses to human immunodeficiency virus type 1 by a DNA vaccine formulated with QS-21 saponin adjuvant via intramuscular and intranasal routes. J. Virol. 1998, 72, 4931-4939.
53. Weiss, W.R.; Ishii, K.J.; Hedstrom, R.C.; Sedegah, M.; Ichino, M.; Barnhart, K.; Klinman, D.M.; Hoffman, S.L. A plasmid encoding murine granulocyte-macrophage colony-stimulating factor increases protection conferred by a malaria DNA vaccine. J. Immunol. 1998, 161, 2325-2332.
54. Arai, H.; Xin, K.Q.; Hamajima, K.; Lu, Y.; Watabe, S.; Takahashi, T.; Toda, S.; Okuda, K.; Kudoh, I.; Suzuki, M.; et al. 8 Br-cAMP enhances both humoral and cell-mediated immune responses induced by an HIV-1 DNA vaccine. Gene Ther. 2000, 7, 694-702.
55. Krieg, A.M.; Yi, A.K.; Matson, S.; Waldschmidt, T.J.; Bishop, G.A.; Teasdale, R.; Koretzky, G.A.; Klinman, D.M. CpG motifs in bacterial DNA trigger direct B-cell activation. Nature 1995, 374, 546-549.
56. Klinman, D.M.; Yamshchikov, G.; Ishigatsubo, Y. Contribution of CpG motifs to the immunogenicity of DNA vaccines. J. Immunol. 1997, 158, 3635-3639.
57. Krieg, A.M.; Wu, T.; Weeratna, R.; Efler, S.M.; Love-Homan, L.; Yang, L.; Yi, A.K.; Short, D.; Davis, H.L. Sequence motifs in adenoviral DNA block immune activation by stimulatory CpG motifs. Proc. Natl. Acad. Sci. USA 1998, 95, 12631-12636.
58. Vollmer, J.; Krieg, A.M. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv. Drug Deliv. Rev. 2009, 61, 195-204.
59. Qi, X.F.; Zheng, L.; Kim, C.S.; Lee, K.J.; Kim, D.H.; Cai, D.Q.; Qin, J.W.; Yu, Y.H.; Wu, Z.; Kim, S.K. CpG oligodeoxynucleotide induces apoptosis and cell cycle arrest in A20 lymphoma cells via TLR9-mediated pathways. Mol. Immunol. 2013, 54, 327-337.
60. Dar, P.A.; Ganesh, K.; Nagarajan, G.; Sarika, S.; Reddy, G.R.; Suryanarayana, V. V. Sindbis virus replicase-based DNA vaccine construct encoding FMDV-specific multivalent epitope gene: Studies on its immune responses in guinea pigs. Scand. J. Immunol. 2012, 76, 345-353.
61. Sun, Y.; Li, H.Y.; Tian, D.Y.; Han, Q.Y.; Zhang, X.; Li, N.; Qiu, H.J. A novel alphavirus replicon-vectored vaccine delivered by adenovirus induces sterile immunity against classical swine fever. Vaccine 2011, 29, 8364-8372.
62. Abdulhaqq, S.A.; Weiner, D.B. DNA vaccines: Developing new strategies to enhance immune responses. Immunol. Res. 2008, 42, 219-232.
63. Halbherr, S.J.; Brostoff, T.; Tippenhauer, M.; Locher, S.; Rentsch, M.B.; Zimmer, G. Vaccination with recombinant RNA replicon particles protects chickens from H5N1 highly pathogenic avian influenza virus. PLoS One 2013, 8, e66059.
64. Ngai, K.L.; Chan, M.C.; Chan, P.K. Replication and transcription activities of ribonucleoprotein complexes reconstituted from avian H5N1, H1N1pdm09 and H3N2 influenza A viruses. PLoS One 2013, 8, e65038.
65. Ulmer, J.B.; Mason, P.W.; Geall, A.; Mandl, C.W. RNA-based vaccines. Vaccine 2012, 30, 4414-4418.
66. Geall, A.J.; Verma, A.; Otten, G.R.; Shaw, C.A.; Hekele, A.; Banerjee, K.; Cu, Y.; Beard, C.W.; Brito, L.A.; Krucker, T.; et al. Nonviral delivery of self-amplifying RNA vaccines. Proc. Natl. Acad. Sci. USA 2012, 109, 14604-14609.
67. Schwartz, L.; Brown, G. V.; Genton, B.; Moorthy, V. S. A review of malaria vaccine clinical projects based on the WHO rainbow table. Malar. J. 2012, 11, doi:10.1186/1475-2875-11-11.
68. Matano, T.; Kobayashi, M.; Igarashi, H.; Takeda, A.; Nakamura, H.; Kano, M.; Sugimoto, C.; Mori, K.; Iida, A.; Hirata, T.; et al. Cytotoxic T lymphocyte-based control of simian immunodeficiency virus replication in a preclinical AIDS vaccine trial. J. Exp. Med. 2004, 199, 1709-1718.
69. Sedegah, M.; Jones, T.R.; Kaur, M.; Hedstrom, R.; Hobart, P.; Tine, J.A.; Hoffman, S.L. Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine. Proc. Natl. Acad. Sci. USA 1998, 95, 7648-7653.
70. Jiang, G.; Shi, M.; Conteh, S.; Richie, N.; Banania, G.; Geneshan, H.; Valencia, A.; Singh, P.; Aguiar, J.; Limbach, K.; et al. Sterile protection against Plasmodium knowlesi in rhesus monkeys from a malaria vaccine: Comparison of heterologous prime boost strategies. PLoS One 2009, 4, e6559.
71. Gabitzsch, E.S.; Xu, Y.; Yoshida, L.H.; Balint, J.; Amalfitano, A.; Jones, F.R. Novel Adenovirus type 5 vaccine platform induces cellular immunity against HIV-1 Gag, Pol, Nef despite the presence of Ad5 immunity. Vaccine 2009, 27, 6394-6398.
72. Xin, K.Q.; Jounai, N.; Someya, K.; Honma, K.; Mizuguchi, H.; Naganawa, S.; Kitamura, K.; Hayakawa, T.; Saha, S.; Takeshita, F.; et al. Prime-boost vaccination with plasmid DNA and a chimeric adenovirus type 5 vector with type 35 fiber induces protective immunity against HIV. Gene Ther. 2005, 12, 1769-1777.
73. Chuang, I.; Sedegah, M.; Cicatelli, S.; Spring, M.; Polhemus, M.; Tamminga, C.; Patterson, N.; Guerrero, M.; Bennett, J.W.; McGrath, S.; et al. DNA prime/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 2013, 8, e55571.
74. Rogers, W.O.; Baird, J.K.; Kumar, A.; Tine, J.A.; Weiss, W.; Aguiar, J.C.; Gowda, K.; Gwadz, R.; Kumar, S.; Gold, M.; et al. Multistage multiantigen heterologous prime boost vaccine for Plasmodium knowlesi malaria provides partial protection in rhesus macaques. Infect. Immun. 2001, 69, 5565-5572.
75. Wilks, A.B.; Christian, E.C.; Seaman, M.S.; Sircar, P.; Carville, A.; Gomez, C.E.; Esteban, M.; Pantaleo, G.; Barouch, D.H.; Letvin, N. L.; et al. Robust vaccine-elicited cellular immune responses in breast milk following systemic simian immunodeficiency virus DNA prime and live virus vector boost vaccination of lactating rhesus monkeys. J. Immunol. 2010, 185, 7097-7106.
76. Fiedler, M.; Kosinska, A.; Schumann, A.; Brovko, O.; Walker, A.; Lu, M.; Johrden, L.; Mayer, A.; Wildner, O.; Roggendorf, M. Prime/Boost immunization with DNA and adenoviral vectors protects from hepatitis D virus (HDV) infection after simultaneous infection with HDV and woodchuck hepatitis virus. J. Virol. 2013, 87, 7708-7716.
77. Winstone, N.; Wilson, A.J.; Morrow, G.; Boggiano, C.; Chiuchiolo, M.J.; Lopez, M.; Kemelman, M.; Ginsberg, A.A.; Mullen, K.; Coleman, J. W.; et al. Enhanced control of pathogenic Simian immunodeficiency virus SIVmac239 replication in macaques immunized with an interleukin-12 plasmid and a DNA prime-viral vector boost vaccine regimen. J. Virol. 2011, 85, 9578-9587.
78. O'Connell, R.J.; Kim, J.H.; Corey, L.; Michael, N.L. Human immunodeficiency virus vaccine trials. Cold Spring Harb. Perspect Med. 2012, 2, a007351.
79. Weiss, W.R.; Kumar, A.; Jiang, G.; Williams, J.; Bostick, A.; Conteh, S.; Fryauff, D.; Aguiar, J.; Singh, M.; O'Hagan, D. T.; et al. Protection of rhesus monkeys by a DNA prime/poxvirus boost malaria vaccine depends on optimal DNA priming and inclusion of blood stage antigens. PLoS One 2007, 2, e1063.